KELLY MARTIC: Open Payments
NPI 1164068250 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,358 in 115 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $570 · 2025 $2,358
Food & beverage: $2,268Education: $90
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 26 | $509 |
| GlaxoSmithKline, LLC. | 17 | $327 |
| GENZYME CORPORATION | 13 | $282 |
| JAZZ PHARMACEUTICALS INC. | 8 | $231 |
| Regeneron Healthcare Solutions, Inc. | 9 | $148 |
| HARMONY BIOSCIENCES LLC | 7 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $123 |
| Verona Pharma, Inc. | 5 | $85 |
| Novartis Pharmaceuticals Corporation | 4 | $79 |
| United Therapeutics Corporation | 3 | $77 |
Products named: DUPIXENT, NUCALA, XYWAV, TEZSPIRE, FASENRA, WAKIX, GLASSIA, XOLAIR.
Industry payments across VA — which companies pay providers there.
